Please login to the form below

Exelixis

This page shows the latest Exelixis news and features for those working in and with pharma, biotech and healthcare.

Daily Brief: Amgen offers Repatha deals in Europe, will Persephone slash Herceptin use?

EUROPE. European approval for Cabometyx in RCC. The European Commission has approved Ipsen and Exelixis’Cabometyx for the first-line treatment of adults with advanced renal cell carcinoma (RCC).

Latest news

Pfizer’s plans for Inlyta go awry with failed adjuvant trial

nivolumab) and Exelixis’multikinase inhibitor Cabometyx (cabozantinib) - backed by strong overall survival data - as well as Eisai’s multikinase drug Lenvima (lenvatinib).
FDA’s year-end approvals take annual tally to 46

The closing few days of 2017 also saw line extension approvals for Exelixis and Novartis. ... therapy. Analysts at Leerink have suggested the new indication could catapult Exelixis’cabozantinib franchise to $1bn in sales in 2025.
Ipsen’s liver cancer treatment clears phase III trial

Ipsen and partner Exelixis are on track to file cancer treatment Cabometyx (cabozantinib) for a new liver cancer indication in the first half of next year, following positive phase III trial
Pfizer's SMO inhibitor boosts survival in blood cancer trial

Other SMO inhibitors are also coming through development meanwhile, notably Exelixis/Bristol-Myers Squibb's BMS 833923 - in phase II testing for CML - and Ignyta/ Eli Lilly's taladegib which is
Ipsen eyes first-line licence for new advanced kidney cancer drug Cabometyx

Ipsen and Exelixis will use the findings to pursue new first-line indications in RCC, a prevalent and difficult to diagnose cancer. ... therapy. French biotech Ipsen signed and exclusive licensing agreement with Exelixis in February for the

More from news
Approximately 5 fully matching, plus 23 partially matching documents found.

Latest Intelligence

Accelerating innovation

Meanwhile, 2016 saw a licensing deal with Cabometyx (cabozantinib) from Californian biotech Exelixis and an agreement with 3B Pharmaceuticals to develop novel oncology radiopharmaceuticals. ... It currently has a second-line licence in Europe, but Ipsen
Charting a course for expansion

Cabometyx accelerates. Earlier this year Ipsen signed another deal to bolster its pipeline by harnessing external innovation, licensing promising cancer drug Cabometyx (cabozantinib) from Californian biotech Exelixis.
Deal Watch March 2016

Two deals involved products at a later stage of development: Dr Reddy's licence for Xenoport's phase II product XP23829 for plaque psoriasis, and Ipsen's licence for Exelixis's ... Collaboration – discovery, development &commercialisation. $965.

More from intelligence
Approximately 0 fully matching, plus 3 partially matching documents found.

Latest appointments

Exelixis appoints Andrew Peters to newly created position

Exelixis appoints Andrew Peters to newly created position. He joins the biotech as its vice president, strategy. ... California, US-based biotechnology group Exelixis has appointed Andrew Peters as vice president of strategy.
Decibel Therapeutics expands leadership team

Prior to this, he was president and chief executive of Exelixis and served as president of Bayer Biotechnology, overseeing the business development, manufacturing and R&D of the company's biological
Frances Heller joins BMS senior management

Heller comes to BMS from Exelixis, a San Francisco-based genomics drug discovery company, where she was executive vice president of business development.

More from appointments
Approximately 1 fully matching, plus 2 partially matching documents found.

Featured jobs

Head of Market Access - International - Based Cambridge: Excellent Basic, Bonus and Flex Benefits

Delivery Manager/ Head of Delivery – Executive Search: Neg

Home based, Senior Medical Writer, Medical Communications: Excellent package

Strategic Planner, Healthcare Advertising: £47, 000 – £53, 000

Account Director, Consumer Healthcare PR, Global PR agency: £50, 000 – £58, 000

Client Services Director - Med Comms: Great salary and bebefits

Principal Medical Writer / Editorial Director – Medical Communic...: £60, 000 - £80, 000

Editorial Director – Medical Education (MedComms): Neg

Healthcare PR Director: £100, 000 – £120, 000 benefits

Home based, Principal Medical Writer, Medical Communications: Excellent package

Account Director, Medical Communications: C£50 – 65, 000 benefits and bonus

Business Unit Head, Medical Communications, London: Excellent package

Home based, Chief Medical Writer, Medical Communications: Excellent package

Senior Account Manager: Competitive salary commensurate with experience

Scientific Communications Director - Oncology – In House Pharma ...: Neg

Senior Medical Writer, Healthcare Advertising Agency: £45, 000 – £50, 000

Home based, Editorial Team Leader, Medical Communications: Excellent package

Client Services Director – Healthcare Advertising - London: Neg

Account Manager: £40, 000 - £45, 000 benefits

Account Manager, Medical Communications and Marketing: £30, 000 – £40, 000 benefits and bonus

Subscribe to our email news alerts

PMHub

Add my company

AMICULUM Limited

AMICULUM® is an independent global healthcare communications, consulting and learning business with a global team of >220 healthcare communications professionals,...

Latest intelligence

Developing advocacy in the pharmaceutical industry.: The importance of advocacy programmes...
GDPR and events. What does the pharma industry need to know?: Many people in the pharma industry still aren’t following the rules set out by the GDPR when it comes to running events and attending tradeshows. But with eye-watering fines for...
Digital trends in B2B sales - how far behind is Pharma?: The modern approach to B2B sales is data-driven, and enabled by digital tools....